使用四因子前激素复合缩物 (4F-PCC) 治疗出血不与治疗抗凝剂使用相关
Elizabeth Uttaro1, Mikaela R Young1, Jennifer Falvey1
1Department of Pharmacy, University of Rochester Medical Center, 601 Elmwood Ave. Box 638, Rochester, NY 14642, USA.
概括
四因子前激素复合缩剂 (4F-PCC) 有效地减少了血液产品的需求,并改善了非抗凝血出血患者的凝血. 已经注意到了血栓栓塞的事件.
科学领域:
- 血液学 血液学 血液学
- 麻醉学 麻醉学
- 关键护理医学 关键护理医学
背景情况:
- 四因子前激素复合物缩剂 (4F-PCC) 是一种潜在的选择,用于管理不接受治疗抗凝药的患者的出血.
- 它可能有助于实现静血,并减少对血液产品输血的需求.
研究的目的:
- 描述4F-PCC在外科和非外科患者的出血管理中的非标签用途.
- 评估其对血液产品使用,排水,凝血参数和血栓栓塞事件的影响.
主要方法:
- 对接受4F-PCC治疗非抗凝血相关出血的成年患者进行了回顾性观察性研究 (2019年6月至2021年7月).
- 主要结果:非标签的4F-PCC使用的描述.
- 二次结局:评估血液产品的使用,排水,凝血研究和血栓栓塞并发症.
主要成果:
- 包括76名患者;66%的出血事件与手术有关,主要是心脏手术患者.
- 4F-PCC的使用 (中位数为1剂/患者,总计1000单位) 显著减少了红细胞,新鲜冷血和血小板的使用.
- 治疗后凝血参数 (PT,INR,aPTT) 得到改善,11%的患者出现了血栓栓塞并发症.
结论:
- 在非抗凝血出血患者中使用低剂量的4F-PCC与血液成分需求的减少有关.
- 观察到PT,INR和aPTT的改善,与其他常见的止血剂一起使用.
- 血栓塞栓性并发症仍然是一个考虑因素.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Disorders of Hemostasis
999
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
999
Introduction to Hemostasis
8.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.4K


